ArticleNature biotechnology2026
Predicting small molecule-RNA interactions without RNA tertiary structures.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neuron-Derived Vesicular circMagi1 Restrains Vascular Repair After Ischemic Stroke by Promoting TRIM65-Mediated ANXA2 Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- In silico designing of small molecules for targeting RNA: current landscape and future directions.Journal of computer-aided molecular design · 2026Review
- Machine Learning for RNA-Targeting Drug Design.Journal of chemical information and modeling · 2026Review
- Decoding the Structural Complexity of Viral RNAs with SHAPE to Guide Antiviral Therapeutics.Viruses · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Small molecules can bind RNAs to regulate their fate and functions, providing promising opportunities for treating human diseases. However, current tools for predicting small molecule-RNA interactions (SRIs) require prior knowledge of RNA tertiary structures. Here we present SMRTnet, a deep learning method that uses multimodal data fusion to integrate two large language models with convolutional and graph attention networks to predict SRIs on the basis of RNA secondary structure. SMRTnet achieves high performance across multiple experimental benchmarks, substantially outperforming existing tools. SMRTnet predictions for ten disease-associated RNA targets identified 40 hits of RNA-targeting small molecules with nanomolar-to-micromolar dissociation constants. Focusing on the MYC internal ribosome entry site, SMRTnet-predicted small molecules showed binding scores correlated closely with observed validation rates. One predicted small molecule downregulated MYC expression, inhibited proliferation and promoted apoptosis in three cancer cell lines. Thus, by eliminating the need for RNA tertiary structures, SMRTnet expands the scope of feasible RNA targets and accelerates the discovery of RNA-targeting therapeutics.
Identifiers
41482542What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.